Samlyn Capital LLC raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 11.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 363,092 shares of the medical research company’s stock after buying an additional 36,297 shares during the period. Thermo Fisher Scientific accounts for about 1.9% of Samlyn Capital LLC’s portfolio, making the stock its 14th largest holding. Samlyn Capital LLC owned about 0.09% of Thermo Fisher Scientific worth $81,256,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. MML Investors Services LLC increased its stake in shares of Thermo Fisher Scientific by 52.2% during the 3rd quarter. MML Investors Services LLC now owns 7,472 shares of the medical research company’s stock worth $1,824,000 after purchasing an additional 2,563 shares during the last quarter. Eagle Asset Management Inc. boosted its holdings in shares of Thermo Fisher Scientific by 2.9% during the 3rd quarter. Eagle Asset Management Inc. now owns 17,411 shares of the medical research company’s stock worth $4,249,000 after buying an additional 498 shares during the period. FIL Ltd boosted its holdings in shares of Thermo Fisher Scientific by 3.3% during the 3rd quarter. FIL Ltd now owns 165,696 shares of the medical research company’s stock worth $40,443,000 after buying an additional 5,314 shares during the period. FMR LLC boosted its holdings in shares of Thermo Fisher Scientific by 18.5% during the 3rd quarter. FMR LLC now owns 6,499,139 shares of the medical research company’s stock worth $1,586,310,000 after buying an additional 1,016,082 shares during the period. Finally, Schroder Investment Management Group boosted its holdings in shares of Thermo Fisher Scientific by 3.2% during the 3rd quarter. Schroder Investment Management Group now owns 1,311,886 shares of the medical research company’s stock worth $320,205,000 after buying an additional 40,386 shares during the period. Hedge funds and other institutional investors own 87.23% of the company’s stock.

Shares of TMO stock opened at $263.81 on Friday. The stock has a market cap of $108.15 billion, a P/E ratio of 24.38, a P/E/G ratio of 1.79 and a beta of 1.13. The company has a quick ratio of 1.24, a current ratio of 1.73 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 52 week low of $199.85 and a 52 week high of $271.70.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, January 30th. The medical research company reported $3.25 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.19 by $0.06. The firm had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.26 billion. Thermo Fisher Scientific had a net margin of 12.06% and a return on equity of 16.86%. The business’s revenue for the quarter was up 7.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.79 EPS. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 12.15 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 16th. Shareholders of record on Friday, March 15th will be issued a $0.19 dividend. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $0.76 dividend on an annualized basis and a yield of 0.29%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.17. Thermo Fisher Scientific’s payout ratio is currently 6.83%.

Several analysts recently commented on TMO shares. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $269.00 target price for the company in a report on Wednesday, November 28th. Needham & Company LLC started coverage on shares of Thermo Fisher Scientific in a report on Wednesday, January 2nd. They set a “strong-buy” rating and a $271.00 target price for the company. Barclays lifted their target price on shares of Thermo Fisher Scientific from $275.00 to $280.00 and gave the stock an “overweight” rating in a report on Thursday, January 3rd. BTIG Research lifted their target price on shares of Thermo Fisher Scientific to $290.00 and gave the stock a “buy” rating in a report on Thursday, January 31st. Finally, Robert W. Baird lifted their target price on shares of Thermo Fisher Scientific from $264.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 30th. Three equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $279.73.

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 2,500 shares of the business’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $266.00, for a total value of $665,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Gregory J. Herrema sold 19,808 shares of the business’s stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $253.29, for a total transaction of $5,017,168.32. Following the completion of the sale, the senior vice president now directly owns 25,688 shares of the company’s stock, valued at approximately $6,506,513.52. The disclosure for this sale can be found here. Insiders sold a total of 36,927 shares of company stock valued at $9,388,124 in the last three months. Insiders own 0.49% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/samlyn-capital-llc-acquires-36297-shares-of-thermo-fisher-scientific-inc-tmo/2912142.html.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Read More: Why do companies pay special dividends?

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.